(UroToday.com) In conjunction with the Scientific Congress held as part of the American Society of Clinical Oncology’s Annual Meeting in May 2020, an Educational Symposium was convened on August 8 to 10th. In a session entitled “Too Many Choices: How to Select the Best Treatment for Your Patient With Kidney Cancer”, Dr. Choueiri from Dana-Farber Cancer Institute and Harvard Medical School presented a plenary talk discussing the subsequent lines of therapy for patients with metastatic renal cell carcinoma (mRCC) who have previously received immunotherapy.